Outlook Wealth Advisors LLC Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Outlook Wealth Advisors LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 643 shares of the company’s stock after purchasing an additional 102 shares during the period. Outlook Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $313,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Riverview Trust Co purchased a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $26,000. Institutional & Family Asset Management LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $28,000. DSM Capital Partners LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $33,000. Finally, Private Wealth Management Group LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $34,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded up $6.74 during midday trading on Friday, reaching $492.26. 590,424 shares of the company were exchanged, compared to its average volume of 492,593. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a fifty day simple moving average of $484.77 and a 200 day simple moving average of $511.61. The stock has a market cap of $40.65 billion, a P/E ratio of 47.65, a PEG ratio of 3.91 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the business earned $2.67 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of a number of recent research reports. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research note on Wednesday. Barclays decreased their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.